Semaglutide is a prescription GLP-1 receptor agonist used for chronic weight management. In 2024, the FDA also approved Wegovy to reduce the risk of major cardiovascular events such as heart attack and stroke in adults with cardiovascular disease who are overweight or obese. That makes it the first weight management medicine with a labeled heart risk reduction benefit for this group. 

The SELECT trial enrolled more than 17,000 adults with prior heart disease and overweight or obesity, but without diabetes. Participants who took semaglutide 2.4 mg weekly had a 20 percent lower risk of the composite of cardiovascular death, heart attack, or stroke compared with placebo over about 40 months. This benefit was consistent across many subgroups and forms the backbone of the FDA’s decision. Subsequent analyses continue to explore how much of the benefit relates to weight loss versus other mechanisms.  

Semaglutide is in a class of medicines called GLP-1's that help people eat less and feel fuller, which supports substantial weight loss. Losing weight improves blood pressure, LDL cholesterol, triglycerides, liver fat, and blood sugar, all of which matter for your heart. GLP-1 drugs may also provide modest blood pressure reductions and improve endothelial function and vascular inflammation, adding potential weight-independent benefits. Scientists are still defining the exact pathways, but the clinical evidence is clear. 

In clinical practice, men often see steady weight loss over several months, with plateaus that can be managed by reinforcing nutrition, physical activity, sleep, and consistency with injections. In SELECT, the average weight loss was meaningful, but the heart benefit appeared even in people who did not lose a dramatic amount of weight, suggesting multiple contributors to protection. Your exact results will vary based on adherence, lifestyle, and medical history. 

Semaglutide for cardiovascular risk reduction is intended for adults who already have cardiovascular disease and who are overweight or obese. It is not a substitute for statins, blood pressure medicines, antiplatelet therapy, or lifestyle changes. Think of it as an added tool that works alongside a full prevention plan.  

The heart of success is a consistent weekly injection plus daily habits that support your arteries. Aim for a protein-forward diet rich in vegetables and fiber, resistance training two to three days per week, and regular cardio. Keep taking your heart medicines unless your clinician changes them. Many men find that as appetite settles, it becomes easier to stick with healthier choices and stay active, which reinforces both weight loss and heart health. The combination is where long-term protection grows. Findings from cardiology groups emphasize layering semaglutide on top of proven therapies, not replacing them.

Protecting your heart is a long game, and you deserve tools that make the work pay off. For men with overweight or obesity and established heart disease, Wegovy offers a meaningful reduction in future heart events when paired with standard care and healthy routines. If you are ready to explore personalized options, Tri-State Men’s Health provides weight loss injections. Our team will review your history, tailor a plan around semaglutide, and support you every step of the way so you can feel stronger and more secure about your heart health.  

Tri-State Men’s Health in the Columbus and Cincinnati Tri-State areas is here to help with compassionate care for men looking for weight loss solutions. We have locations in West Chester, Ohio, Louisville, Kentucky, Dayton, Ohio, Hilliard, Ohio, Westerville, Ohio, and Crestview Hills, Kentucky, to serve you.

Contact us today to schedule an appointment.

Disclaimer: Individual results may vary. We cannot guarantee specific outcomes from these services.